CLOs on the Move

Success TMS

www.successtms.com

 
Get relief from depression in under 8 weeks. Safe & FDA approved. Covered by Insurance & Medicare. Get your FREE consultation. Book an appointment Today!
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.successtms.com
  • 8845, North Military Trail
    West Palm Beach, FL USA 33410
  • Phone: 855.679.1034

Executives

Name Title Contact Details

Similar Companies

Sizewise

We offer bariatric and non-bariatric medical equipment including bed frames, therapeutic mattresses, and mobility items for patients of all ages.

United Drugs

United Drugs is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ZYUS

ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of phyto-therapeutics, commonly known as plant-made solutions. We are committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for our patients.

BVI

Beaver-Visitec International (BVI) is a highly regarded ophthalmic device manufacturer offering a broad range of single use instruments & custom procedure packs

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.